CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
First Claim
1. A method of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that disrupts the interaction between Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1), wherein the antibody or antigen-binding portion thereof binds specifically to PD-1 or to PD-11.
0 Assignments
0 Petitions
Accused Products
Abstract
The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
109 Citations
23 Claims
- 1. A method of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that disrupts the interaction between Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1), wherein the antibody or antigen-binding portion thereof binds specifically to PD-1 or to PD-11.
-
4. A method for immunotherapy of a subject afflicted with cancer, which method comprises:
-
(a) selecting a subject that is a suitable candidate for immunotherapy, the selecting comprising; (i) providing a test tissue sample obtained from a patient with cancer of the tissue, the test tissue sample comprising tumor cells and tumor-infiltrating inflammatory cells; (ii) assessing the proportion of cells in the test tissue sample that express PD-L1 on the cell surface; and (iii) selecting the subject as a suitable candidate based on an assessment that the proportion of cells in the test tissue sample that express PD-L1 on the cell surface exceeds a predetermined threshold level; and (b) administering a composition comprising a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. - View Dependent Claims (5, 6, 7, 8, 9)
-
-
10. A method for treatment of a subject afflicted with cancer, which method comprises:
-
(a) selecting a subject that is not suitable for anti-PD-1 antibody immunotherapy, the selecting comprising; (i) providing a test tissue sample obtained from a patient with cancer of the tissue, the test tissue sample comprising tumor cells and tumor-infiltrating inflammatory cells; (ii) assessing the proportion of cells in the test tissue sample that express PD-L1 on the cell surface; and (iii) selecting the subject as not suitable for anti-PD-1 antibody immunotherapy based on an assessment that the proportion of cells in the test tissue sample that express PD-L1 on the cell surface is less than a predetermined threshold level; and (b) administering a standard-of-care therapeutic other than an anti-PD-1 antibody to the selected subject. - View Dependent Claims (11, 12, 13)
-
-
14. A method of treating a subject afflicted with a cancer comprising administering to the subject:
-
(a) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Programmed Death-1 (PD-1); and (b) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4); each antibody being administered at a dosage ranging from 0.1 to 20.0 mg/kg body weight in a concurrent regimen comprising; (i) an induction dosing schedule comprising combined administration of the anti-PD-1 and anti-CTLA-4 antibodies at a dosing frequency of at least once every 2, 3 or 4 weeks, or at least once a month, for at least 2, 4, 6, 8 or 10 doses, followed by administration of the anti-PD-1 alone at a dosing frequency of at least once every 2, 3 or 4 weeks, or at least once a month, for at least 2, 4, 6, 8 or 12 doses;
followed by(ii) a maintenance dosing schedule comprising combined administration of the anti-PD-1 and anti-CTLA-4 antibodies at a dosing frequency of at least once every 8, 12 or 16 weeks, or at least once a quarter, for at least 4, 6, 8, 10, 12 or 16 doses. - View Dependent Claims (15, 20, 22, 23)
-
- 16. A method of treating a subject afflicted with a cancer, the subject having previously been treated with an anti-CTLA-4 antibody, which method comprises administering to the subject in a sequenced regimen an antibody or an antigen-binding portion thereof that specifically binds to and inhibits PD-1 at a dosage ranging from 0.1 to 20.0 mg/kg body weight and at a dosing frequency of at least once every week, at least once every 2, 3 or 4 weeks, or at least once a month, for up to 6 to up to 72 doses.
-
18. The method of 16, wherein the anti-CTLA-4 antibody is ipilimumab.
-
19. (canceled)
Specification